Deisseroth, Hegemann and Nagel share the medicine Nobel for optogenetics

The Nobel Assembly at Karolinska Institutet awarded the 2026 prize in physiology or medicine on Monday to Karl Deisseroth, Peter Hegemann and Georg Nagel for discoveries on light-gated ion channels and optogenetics. The three share 12 million Swedish kronor, about 1.2 million dollars. Deisseroth is 54. Hegemann is 71. Nagel is 73.

Optogenetics uses light to control single nerve cells. Thomas Perlmann, speaking for the assembly, said the method makes it possible to switch the activity of individual nerve cells on or off in a living brain. Anna Wedell said it was the first time researchers could start to see how the brain processes information and how neurons interact across it. Those two sentences are the practical claim. A drug bathes a circuit. A light pulse, delivered to a cell that has been given a light-sensitive channel, hits one cell.

The biology came before the name. Hegemann and Nagel worked on channelrhodopsins, proteins from algae that open a pore when light hits them. Findings were published in 2003. In 2005 the tool was shown in rat nerve cells: put the channel in the cell, shine the right wavelength, the cell fires. The method was named optogenetics in 2006. Deisseroth's laboratory at Stanford turned that protein into a system other neuroscientists could use on behaving animals, with fibre optics and genetic targeting. Hegemann has been at Humboldt University in Berlin. Nagel has been at the University of Wurzburg.

Deisseroth said he had not yet gone to sleep, that he is a night owl, and that he did not expect to sleep for a while. Hegemann called the message unbelievable. Nagel said he had thought it would not happen, and that other people had kept telling him it would. The quotes are the human record of a prize that has been predicted in neuroscience departments for a decade. Monday made the prediction a citation.

What the method changed in laboratories is the experiment, not the disease list. Before optogenetics, a researcher who wanted to test whether one class of neuron caused a behaviour had to lesion it, stimulate a whole region, or infer the link from timing. With a channelrhodopsin in that class, the same animal can be run with the light on and the light off. Fear conditioning, movement initiation, thirst, and memory retrieval have all been probed that way in mice. The clinical distance is still large. Getting a gene and a light source into a human circuit is a therapy problem, not a discovery problem. Trials that use optogenetic proteins in the eye, for some inherited blindness, are the nearest clinical cousin. The Nobel citation is for the channels and the method, not for an approved treatment.

The split of credit matches the split of labour. Hegemann and Nagel identified and characterised the light-gated channel. Deisseroth showed what a neuroscientist could do with it in a living brain. A reader who has seen only the headline "optogenetics wins" misses that order. The protein is German work from the early 2000s. The animal system that made the protein famous is the Stanford step. Stockholm gave the prize to both steps, twenty years after the naming.

Tuesday's physics prize, to Francis Halzen for IceCube, sits next to this one on the calendar. Both prizes honour a way of seeing a process that does not announce itself: a neutrino that almost never hits anything, a nerve cell that cannot be switched by hand. The medicine prize's useful number for a non-specialist is the gap between the papers and the award. Publication in 2003, a name in 2006, a Nobel in 2026. The tool has been in ordinary use in neuroscience for most of that gap. The citation formalises a method the field already treated as basic equipment.